This Patient Information has been approved by the U. Prograf, like other calcineurin-inhibitors, can cause acute or chronic nephrotoxicity, particularly when used in high doses.
GVHD was diagnosed and graded according to standard clinical and pathological characteristics. Five assumptions were made for the purposes of this study.
Prograf injection should be discontinued as soon as the patient can tolerate oral administration of Prograf capsules, usually within days.
The trial population had a mean age of 44 years range 0. Clearance of tacrolimus was calculated from the blood levels for patients during intravenous dosing and normalized by ideal body weight. This assumption has been applied successfully in the therapeutic drug monitoring of oral phenytoin. Due to its potential for nephrotoxicity, consideration should be given to dosing Prograf at the lower end of the therapeutic dosing range in patients who have received a liver or heart transplant and have pre-existing renal impairment.
Coagulation disorder, ecchymosishaematocrit increased, haemoglobin abnormal, hypochromic anemia, leukocytosispolycythemiaprothrombin decreased, serum iron decreased. Bilirubin was between 2 - 9. If you would like more information, talk with your doctor. Acne, alopeciaexfoliative dermatitisfungal dermatitis, herpes simplex, herpes zosterhirsutismneoplasm skin benignskin discoloration, skin disorder, skin ulcer, sweating.
The pharmacokinetic parameters obtained were similar for both groups. There were no significant differences in neither trough concentrations the first week after transplantation nor time to target trough concentration between patients later experiencing BPAR or not. This condition appears reversible in most cases following dose reduction or discontinuance of therapy.
Limited overdosage experience is available.
Given the narrow therapeutic window of tacrolimus, achieving complete steady-state prior to performing therapeutic drug monitoring is often not feasible clinically. Bone Marrow Transplant ; This trial excluded pediatric patients, but did allow enrollment of subjects with renal dysfunction, fulminant hepatic failure in Stage IV encephalopathy, and cancers other than primary hepatic with metastases.
As the effect of chronic exposure to tacrolimus in healthy infants is not established, patients maintained on Prograf should discontinue nursing taking into consideration importance of drug to the mother.
Use with sirolimus is not recommended in liver and heart transplant. The tacrolimus dose regimen was 0. It is practically insoluble in water, freely soluble in ethanol, and very soluble in methanol and chloroform.
Access material from all our publications in your subject area: Two trials were conducted for Prograf-based immunosuppression in conjunction with MMF and corticosteroids.
Arthralgiacramps, generalized spasm, joint disorder, leg cramps, myalgiamyasthenia, osteoporosis. Tacrolimus blood concentrations from all subjects were simultaneously analyzed to obtain the population parameters of interest.
Acute renal failurecystitis haemorrhagic, hemolytic -uremic syndrome, micturition disorder.
This trial was conducted entirely outside of the United States.
- viagra effects on blood pressure
- dosage of vibramycin for acne
- what happens if you drink and take klonopin
- clotrimazole for herpes
- wellbutrin leukopenia
- acquisto cialis farmacia italiana
- side effects of overdose of gabapentin
- assessment prior to administering digoxin
- how much can you sell hydrocodone 10-325 for
- metoprolol tartrate sleep apnea